Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | ATF4 | P18848 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26550828 | 0.84 | CHRM1 (0.41) | CHRM1ATF4HSD11B1ADORA2AADORA1 | |
| SCHEMBL24471486 | 0.79 | CHRM1 (0.42) | CHRM1ATF4HSD11B1NPSR1MEN1 | |
| SCHEMBL17213668 | 0.77 | CHRM1 (0.41) | CHRM1HSD11B1NPSR1ALDH1A1MAPT | |
| SCHEMBL2445606 | 0.76 | NPSR1 (0.46) | CHRM1HSD11B1ADORA2AADORA1NPSR1 | |
| SCHEMBL22874279 | 0.75 | ATF4 (0.35) | ATF4 | |
| SCHEMBL24471410 | 0.74 | CHRM1 (0.37) | CHRM1ATF4NPSR1MEN1ALDH1A1 | |
| SCHEMBL4743712 | 0.73 | CHRM1 (0.38) | CHRM1HSD11B1ADORA2AADORA1NPSR1 | |
| SCHEMBL27390289 | 0.73 | CHRM1 (0.38) | CHRM1HSD11B1ADORA2AADORA1NPSR1 | |
| SCHEMBL18402657 | 0.72 | CHRM1 (0.43) | CHRM1HSD11B1ADORA2AADORA1NPSR1 | |
| SCHEMBL22874365 | 0.72 | CHRM1 (0.39) | CHRM1HSD11B1ADORA2AADORA1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787814-B2 | Method for preparing 2-indolinospirone compound and intermediate thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-10-17 | — | — | US | disclosed |
| US-11787814-B2 | Method for preparing 2-indolinospirone compound and intermediate thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-10-17 | — | — | US | disclosed |
| WO-2021004516-A1 | METHOD FOR PREPARING 2-INDOLINOSPIRONE COMPOUND AND INTERMEDIATE THEREOF | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787814-B2 | Method for preparing 2-indolinospirone compound and intermediate thereof | CYP51A1, CYP11B2, CYP3A5 | CHRM1 987/4885ATF4 4184/4885HSD11B1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.